Incyte s Q4 Revenues Jump, while Losses Widen: $240M Revenues Expected for 2001 | GenomeWeb

NEW YORK, Feb 1 – Bolstered by solid revenues on its custom genomics programs, Incyte posted increased fourth quarter revenues Thursday, and forecasted a continuing growth curve throughout 2001.

Incyte expects to post revenues of between $220 and $240 million in the coming year, said John Vuko, Incyte’s Chief Financial officer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.